B rain metastases(BM) are the most common central nervous system neoplasm in adults and can be found in 10-40% of patients with cancer. [1] The average life expectancy of patients with multifocal metastases undergoing whole-brain radiation therapy (WBRT) is 4-6 months. Pa-tients with oligometastases treated with stereotactic radiosurgery and/or fractionated stereotactic radiotherapy (SRS/SRT) have an estimated survival of 12 months or more. [2][3][4] Grade 4 gliomas (glioblastoma multiforme, GBM) make up the majority of central nervous system (CNS) tumours.Objectives: Due to a lack of similar research, this retrospective analysis of patients indicated the blood parameters of pre-treatment inflammatory markers to assess the diagnostic accuracy of the protein nutritional index (PNI), platelet albumin ratio (PAR) and red cell distribution width (RDW) in patients with brain metastasis (BM) and glioblastome multiforme (GBM). Methods: Clinical and laboratory data were retrospectively collected from a group of 244 patients and randomly divided into GBM (142 patients) and BM (102 patients). PNI, PAR and RDW values were calculated 3 weeks before from a chosen pre-treatment modality (preoperative or pre-radiotherapy). Results: The neutrophil and trombocyte counts were higher, while the lymphocyte count was lower in patients with GBM and BM. A lower PNI value (p=0.019), higher PAR value (p=0.027) and higher RDW value (p=0.008) were independent diagnostic factors for brain metastasis. Although both PNI and PAR were diagnostically accurate, RDW had proven the highest accuracy of them all. Conclusion: Our study shows that the retrospective analysis provided a robust and independent diganostic value for pretreatment. The RDW ≥14.3%, PNI ≤ 49.1%, and Plt/alb ≥ 61.6 ratios also support this diagnostic index for differentiating between GBM and BM.